News >

Forde Focuses on Future of Early-Stage NSCLC

Caroline Seymour
Published: Friday, Sep 21, 2018

Patrick M. Forde, MBBCh

Patrick M. Forde, MBBCh

Median survival has nearly tripled in patients with early-stage non–small cell lung cancer (NSCLC), a statistic that is largely attributed to immunotherapeutic agents, explained Patrick M. Forde, MBBCh, an assistant professor of oncology at Johns Hopkins Medicine.

An influential trial in this setting was the PACIFIC trial, in which the median progression-free survival (PFS) was 16.8 months with durvalumab (Imfinzi) versus 5.6 months with placebo in patients with locally advanced unresectable NSCLC (HR, 0.52; 95% CI, 0.42-0.65; P <.0001).1 Patients were treated with the PD-L1 inhibitor following standard chemoradiotherapy.

Additional research is now investigating whether neoadjuvant immunotherapy can be adopted into earlier stages of resectable disease. In a pilot study published in the New England Journal of Medicine, 21 treatment-naïve patients with surgically resectable disease were given 2 preoperative doses of nivolumab (Opdivo; NCT02259621). Neoadjuvant nivolumab induced a major pathological response in 9 of 20 patients (45%) whose tumors were completely resected.2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication